SuspendedPhase 2NCT04668365

Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma

Studying Epstein-Barr virus-positive diffuse large B-cell lymphoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Henan Cancer Hospital
Principal Investigator
Zhihua Yao, M.D. Ph.D
Henan Cancer Hospital
Intervention
Rituximab(drug)
Enrollment
59 enrolled
Eligibility
18-75 years · All sexes
Timeline
20202025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04668365 on ClinicalTrials.gov

Other trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Epstein-Barr virus-positive diffuse large B-cell lymphoma

← Back to all trials